Reuters logo
BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission
2017年10月23日 / 上午11点08分 / 1 个月前

BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission

Oct 23 (Reuters) - Merck & Co Inc

* AstraZeneca and Merck rapidly advance LYNPARZA (olaparib) in Japan with a second regulatory submission

* Merck - ‍submitted NDA to Japan’s PMDA for use of LYNPARZA(olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with decision expected in H2 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below